What is BPC-157?
BPC-157 is a 15-amino-acid research peptide. Selected animal injury studies and a two-person human safety pilot explore different questions; neither establishes treatment benefit for injured patients.
Video overview · 2:47
BPC-157: What the Research Actually Shows (Rats vs. People)
Where it comes from, how it might work, what the rat and cell studies found, how little human data exists, the one registered human trial, and its safety and legal status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
BPC-157 is a short chain of fifteen amino acids, studied in laboratories for tissue repair. It is not an approved medicine in the United States, and most of the research behind it comes from animals. Here is what is actually known.
The letters B P C stand for Body Protection Compound. BPC-157 is a lab-made copy of a small piece of a protein found in human stomach juice. Much of the early research came from a team at the University of Zagreb in Croatia. Today it is sold online as a research chemical, a label that means it has not been tested or approved as a medicine.
No one knows exactly how BPC-157 works. One idea comes from a 2014 study of rat tendon cells. Cells exposed to it made more receptors for growth hormone, so they may respond more strongly to the body's own repair signals. That is a hypothesis from cells in a dish, not proof of what happens in an injured person.
Most BPC-157 research comes from rats. In tendon and ligament injury experiments, treated animals showed better healing measures than untreated ones. These are early, lab-stage findings, and animal results often fail to carry over to people.
In people, the evidence is thin. One published pilot followed just two adults for a few days and reported no side effects. A study that small and that short cannot show whether it works, or catch rare or delayed harms.
Human trials are only starting. One small study after rotator cuff surgery is registered, but it has not started recruiting yet. Until results are published, nobody can say whether BPC-157 helps injured people.
In animal toxicity testing, researchers reported no serious harm beyond mild irritation where it was applied, but animal results cannot show it is safe for people. The FDA has said there is not enough information to know whether it causes harm in people, and it once listed BPC-157 among compounding ingredients that may carry significant safety risks. It is not FDA approved, and the World Anti-Doping Agency prohibits it in sport.
A few questions come up often. Does BPC-157 heal tendons in people? PepsRadar's claim check rates that unproven, because the healing results come from rats and cells. Is BPC-157 with TB-500 a proven combination? No trial has tested them together. And does a seller's lab certificate mean a vial is safe? No. A purity test checks what is in the vial, not whether it is safe to use.
The bottom line: promising animal research, very little human data, and real trials only now getting started. For every study and source, see the BPC-157 profile on PepsRadar dot com.
Biological role or research focus
Experimental tissue-repair research.
A tendon-cell experiment cannot establish recovery time, pain relief, or a reliable injury treatment in people.
Role reference: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
Names you may encounter
BPC 157 · BPC157
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental pentadecapeptide
- Main research area
- Tendon and tissue biology
- Evidence featured
- Rat tendon-cell study
- Source check
- October 4, 2026
Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
Quick answers
- Is BPC-157 FDA approved?
- No. No FDA-approved drug contains BPC-157. Source ↗
- Is BPC-157 safe?
- BPC-157 is unapproved. Human safety data are limited to a two-person pilot and a small chart review, and FDA says it lacks the information to know whether it causes harm in people. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is BPC-157 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S0 Non-approved substances). Source ↗
- Has the FDA taken action over BPC-157?
- Yes. Our records list 5 FDA actions naming it, most recently on October 28, 2026: HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Growth-hormone receptor experiment (2014) | Rat tendon-cell study | Fibroblasts isolated from rat Achilles tendons. |
| Achilles tendon transection model (2003) | Animal + cell study | Rats with transected Achilles tendons, with additional cultured tendon-cell experiments. |
| Medial collateral ligament healing (2010) | Animal study | Rats after surgical transection of the medial collateral ligament. |
| BPC-157 · knee-pain chart review (2021) | Retrospective human chart review | 16 patients at one U.S. primary-care hormone clinic, reached by phone 6–12 months after a knee injection; 12 received BPC-157 alone and 4 received BPC-157 with thymosin beta-4. |
| BPC-157 · two-person safety pilot (2025) | Uncontrolled human pilot | Two adults aged 58 and 68 who had both received intravenous BPC-157 before the study. |
Claim check
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Rat tendon-cell study · 2014
Growth-hormone receptor experiment
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.
- Population / model
- Fibroblasts isolated from rat Achilles tendons.
- Study design
- Cell-culture experiments measured growth-hormone receptor expression and responses to growth hormone.
- Main finding
- BPC-157 increased receptor expression, and the treated cells showed a greater proliferative response to growth hormone.
- Limits & context
- A change in isolated cells is a possible mechanism, not a measured improvement in human tendon strength, pain, return to sport, or long-term safety.
Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
Animal + cell study · 2003
Achilles tendon transection model
Did tissue and functional measures change after a surgically created tendon injury?
- Population / model
- Rats with transected Achilles tendons, with additional cultured tendon-cell experiments.
- Study design
- Controlled injury model with functional, mechanical, microscopic, and gross assessments over 14 days.
- Main finding
- The treated animals had better reported tendon mechanics, functional scores, and tissue organization than controls. Cell experiments also examined responses to an inhibitor of cell growth.
- How to read it
- This paper connects tissue observations with mechanical and functional measurements within a rat model.
- Limits & context
- An acute surgical injury in rats differs from human tendinopathy or rehabilitation. These findings do not establish a human recovery time, effective clinical treatment, or long-term safety.
Source: Staresinic et al. · Journal of Orthopaedic Research · 2003 ↗
Animal study · 2010
Medial collateral ligament healing
Was the repair signal also observed in a ligament injury model?
- Population / model
- Rats after surgical transection of the medial collateral ligament.
- Study design
- Controlled experiments with different administration routes and follow-up extending to 90 days.
- Main finding
- The authors reported improvements in functional, mechanical, gross, and histological measures of ligament healing.
- How to read it
- A ligament model broadens the preclinical questions beyond the earlier tendon experiment.
- Limits & context
- This remains animal evidence. Several routes studied in a model do not establish equivalent exposure, benefit, or safety in people.
Source: Cerovecki et al. · Journal of Orthopaedic Research · 2010 ↗
Retrospective human chart review · 2021
BPC-157 · knee-pain chart review
What did the clinic chart review of knee injections report?
- Population / model
- 16 patients at one U.S. primary-care hormone clinic, reached by phone 6–12 months after a knee injection; 12 received BPC-157 alone and 4 received BPC-157 with thymosin beta-4.
- Study design
- One-year retrospective chart review with a phone survey of pain relief; no control group, no blinding, and no standard pain or function scales.
- Main finding
- The authors reported that 14 of 16 patients (87.5%) described significant knee-pain relief, including 11 of 12 who received BPC-157 alone.
- How to read it
- Self-reported relief recalled months later, without a comparison group, cannot separate a drug effect from placebo, natural recovery or other treatments.
- Limits & context
- The knee problems varied, follow-up was inconsistent, and no imaging or function measures were used. The study did not systematically record side effects, so it says little about safety. Controlled trials would be needed to support a benefit.
Uncontrolled human pilot · 2025
BPC-157 · two-person safety pilot
What can the recent intravenous pilot establish?
- Population / model
- Two adults aged 58 and 68 who had both received intravenous BPC-157 before the study.
- Study design
- Single private-clinic pilot with blood tests, vital signs, and reported symptoms over three days; no comparator.
- Main finding
- No reported side effects or measurable changes in the tested organ-function biomarkers were observed during the short monitoring period.
- How to read it
- Two previously exposed participants provide a very limited observation, not evidence of general safety.
- Limits & context
- The study cannot detect uncommon or delayed harms, establish injury-healing efficacy, or validate research-use products. The authors’ broad safety conclusion exceeds what this design can establish. Larger controlled studies and pharmaceutical-quality identity checks remain necessary.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
1 registered study names BPC-157 as an intervention; 0 are recruiting or under way, 1 has not started recruiting yet and 0 completed. Checked November 14, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery NCT07803250 · University of Arkansas | Not yet recruiting | Phase 1 | 2027-01-01 | 30 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
BPC-157 is unapproved. Human safety data are limited to a two-person pilot and a small chart review, and FDA says it lacks the information to know whether it causes harm in people.
A two-person pilot checked blood tests for a few days and reported no side effects, and a small retrospective knee-pain chart review had no control group. Neither can detect uncommon or delayed harms.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
- Product identity and purity of research-market products are unverified
Harms seen in animal or lab studies
- A published animal toxicity program (mice, rats, rabbits, dogs) reported no serious toxicity but mild local irritation; animal results do not establish human safety
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · Intravenous BPC-157 two-person pilot (2025) ↗ · BPC-157 knee pain retrospective chart review (2021) ↗ · Preclinical safety evaluation of BPC-157 (2020) ↗
Safety evidence & remaining uncertainty
FDA flags limited safety information. The tendon-cell paper cannot measure systemic adverse effects, immune reactions, or long-term risks. A vendor purity result would answer a different question from clinical safety.
Source: FDA · Peptide compounding safety concerns ↗
Human pilot does not establish safety
The recent pilot monitored only two previously exposed adults for three days. It cannot exclude delayed or uncommon harms and did not test injury-healing benefit.
Source: BPC-157 · two-person safety pilot · 2025 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "BPC-157". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA nonetheless presented BPC-157 (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 23, 2026, proposing that it NOT be added to the 503A bulks list. On October 28, 2026, HHS filed an interim enforcement discretion policy covering BPC-157 (Federal Register 2026-22192): HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding it while rulemaking proceeds. That is not listing on the 503A bulks list and not FDA approval. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S0 Non-approved substances
Named explicitly as an example in S0. source
FDA actions
- HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). BPC-157 is one of six peptides in its Appendix A (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with these peptides while FDA develops the 503A bulks list by rulemaking. It is not an FDA approval, does not add BPC-157 to the 503A bulks list, is not binding, and HHS may revisit it if a safety signal or quality problem arises. The comment period on regulations.gov closed on November 13, 2026 (docket HHS-OASH-2026-0496). (2026-10-28) source
- FDA and HHS sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review (received October 14, 2026; RIN 0910-ZD94). OMB review concluded and HHS filed the policy on October 28, 2026 (see above). (2026-10-14) source
- FDA presented BPC-157 (free base and acetate) to its Pharmacy Compounding Advisory Committee (July 23, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
- FDA warning letter (Warrior Labz) citing BPC-157 and TB-500 injectable and nasal products sold online as unapproved new drugs. (2023-06-12) source
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing BPC 157 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
This profile covers experimental tissue biology. The linked experiment does not provide an established clinical use, recovery timetable, or validated combination with TB-500. Human clinical claims need their own controlled evidence.
Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
One proposed pathway involves changing growth-hormone receptor expression in tendon fibroblasts. This offers a cellular hypothesis for repair research without establishing how an injured human tendon responds.
Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- A tendon-cell experiment cannot establish recovery time, pain relief, or a reliable injury treatment in people.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does a tendon-cell result prove faster injury recovery?
No. Cell proliferation, tendon strength, pain, and return to activity are separate outcomes.
Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
Can BPC-157 and TB-500 be treated as a proven combination?
No controlled trial of the combination exists in our sources; the only human report that includes it is a small subgroup in an uncontrolled knee-pain chart review. Evidence for either material alone cannot establish the effectiveness or safety of their combination.
Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
What does the Medial collateral ligament healing study show, and what does it not?
A ligament model broadens the preclinical questions beyond the earlier tendon experiment. This remains animal evidence. Several routes studied in a model do not establish equivalent exposure, benefit, or safety in people.
Source: Cerovecki et al. · Journal of Orthopaedic Research · 2010 ↗
References & editorial record
- FDA · Compounding safety concerns ↗
- BPC-157 tendon-cell study (2014) ↗
- Staresinic et al. · Journal of Orthopaedic Research · 2003 ↗
- Cerovecki et al. · Journal of Orthopaedic Research · 2010 ↗
- BPC-157 · knee-pain chart review · 2021 ↗
- BPC-157 · two-person safety pilot · 2025 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
From a promising mechanism to a useful finding
A practical way to read peptide research without turning an interesting experiment into a clinical promise.
Read the guide →RESEARCH FIELD GUIDE
BPC-157 vs TB-500: compare the research, not the reputation
Tendon models, fragment identity, and a tiny eye-drop trial answer different questions. Here is how to keep them separate.
Read the guide →RESEARCH FIELD GUIDE
Are peptides legal? FDA approval, research-use labels and steroids, explained
Some peptides are FDA-approved prescription drugs; most sold online are not. What the FDA has actually said, how pharmacy compounding fits in, and why peptides are not steroids.
Read the guide →RESEARCH FIELD GUIDE
How to tell if your peptides are real: check the COA with the lab
You can’t see purity in a vial, but you can check whether the testing lab really issued the certificate you were shown. Here is how, and what our own checks turned up.
Read the guide →RESEARCH FIELD GUIDE
How to read a peptide COA (certificate of analysis) without mistaking it for a guarantee
A worked example separates directory references, certificate IDs, batch numbers, reported results, and unanswered questions.
Read the guide →RESEARCH FIELD GUIDE
Is BPC-157 FDA approved? What the FDA and the research actually say
No. BPC-157 is not approved by the FDA for any use, the FDA has flagged it as a compounding safety risk, and its healing evidence comes almost entirely from animal studies.
Read the guide →RESEARCH FIELD GUIDE
Tissue repair peptides: which have actually been tested in people?
A roundup of popular tissue repair peptides and what has been tested in people: BPC-157's tiny human record, thymosin beta-4 eye and ulcer trials, GHK-Cu skin studies, TP-508 and LL-37 wound trials, plus FDA and WADA status.
Read the guide →RESEARCH FIELD GUIDE
Which peptides can pharmacies compound now? The 2026 HHS peptide policy explained
HHS says it will not act against licensed 503A compounders using six peptides while FDA writes its bulks-list rules. That is not FDA approval, and FDA staff found little or no human data for any of the six.
Read the guide →







